Introduction
============

In the People's Republic of China, recent health statistics data have revealed the increasing trend of morbidity and mortality of people with liver cancer in a setting of an estimated 100 million carriers of hepatitis B virus (HBV), accounting for the most common cancer and the second leading cause of cancer-related death.[@b1-ott-10-1181] Although the development of comprehensive treatment and advances in surgery have benefited liver cancer patients, the prognosis remains poor mainly due to high recurrence and metastasis rates after surgical resection, especially for HBV-positive hepatocellular carcinoma.[@b2-ott-10-1181],[@b3-ott-10-1181] Classification of patients facilitates predicting survival, thus helping to provide individualized therapies and improve clinical survival outcomes; therefore, the importance of prognostic and predictive biomarkers has been increasingly recognized.[@b4-ott-10-1181] However, biomarkers definitely associated with prognosis are currently limited to clinicopathological characteristics which can only be assessed through postoperative histological studies and findings during surgery, such as histological stage, the pathological type, or TNM stage.[@b5-ott-10-1181]--[@b9-ott-10-1181] So novel pretreatment biomarkers characterized by affordability and technical feasibility are required.

Inflammation plays an important role in the development of various malignant tumors.[@b10-ott-10-1181] Inflammatory cells can secrete various proangiogenic factors and inflammatory mediators, thus prompting a favorable cancer-related inflammatory microenvironment, which can further promote vascular invasion and suppress the host immune system.[@b11-ott-10-1181]--[@b13-ott-10-1181] Otherwise, various cytokines secreted by tumors can influence the blood cells associated with host inflammatory and immunity, such as the neutrophilic, lymphocytic, and monocyte cells and blood platelets.[@b14-ott-10-1181],[@b15-ott-10-1181]

It has been confirmed that several inflammatory response-related biomarkers can potentially predict prognosis of various types of malignancies, such as the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio (LMR).[@b16-ott-10-1181]--[@b20-ott-10-1181] Otherwise, we have analyzed the prognostic significance of LMR in 144 patients with pancreatic adenocarcinoma, and found higher preoperative LMR was significantly associated with better survival.[@b21-ott-10-1181] However, there was still no report on the association of preoperative LMR with survival of resected HBV-positive hepatocellular carcinoma. In this study, we try to evaluate the prognostic significance of preoperative LMR in HBV-positive hepatocellular carcinoma patients who underwent curative surgery.

Patients and methods
====================

Patients
--------

Two hundred and fifty-three patients with primary hepatocellular carcinoma who underwent curative resection at the First Department of General Surgery in The First Affiliated Hospital of Xin-Xiang Medical University were enrolled in this study between July 1, 2008 and July 1, 2014. Inclusion criteria included histologically confirmed hepatocellular carcinoma and positive HBsAg, age more than 18 years, and life expectancy more than 6 months. The exclusion criteria included acute and severe preoperative lymphatic system or malignant hematologic conditions or adjuvant treatments. The standard of curative resection was consistent with the National Comprehensive Cancer Network guidelines for hepatobiliary cancer. Clinicopathologic characteristics of all patients were collected from the medical records by one surgeon and checked by another surgeon, including sex, age, tumor size, liver cirrhosis, Child-Pugh stage, HBsAg, AFP level, Barcelona Clinic Liver Cancer (BCLC) stage, TNM stage, tumor site an size, pathological differentiation, and operation type. Histopathological and TNM staging were assessed through postoperative histopathological examination and clinical assessment, respectively. Absolute lymphocyte count and monocyte count were obtained from a routine blood test on the day before surgery. LMR was calculated using the following equation: $$\text{LMR} = \frac{\text{absolute~lymphocyte~count}}{\text{absolute~monocyte~ratio}}.$$

Follow-up
---------

All patients were followed-up through regular outpatient visits; physical examination and laboratory examinations including AFP every 3 months for the first 2 years, every 6 months for the next 3 years, and once annually thereafter. Enhanced abdominal computed tomography (CT) or magnetic resonance imaging (MRI) scans were obtained generally every year. Clinical follow-up lasted from surgery to either death or the endpoint of study (ie, June 2015). This study had been approved by the Ethics Committee of The First Affiliated Hospital of Xin-Xiang Medical University. Written informed consent was obtained from all patients.

Statistical analysis
--------------------

Statistical analyses were performed by SPSS 20.0 (IBM Corporation, Armonk, NY, USA). *P*\<0.05 (two sided) was considered as statistically significant. The optimal cutoff values for the LMR were confirmed through receiver operating characteristic (ROC) curve analysis. Overall survival (OS) was accurately defined as the duration from surgery to death, whereas recurrence-free survival (RFS) was calculated as the duration from surgery to tumor recurrence. Qualitative variables were analyzed through the *χ*^2^ test or Fisher's exact test, while quantitative values were evaluated by independent Student's *t*-test. The OS and RFS curves were studied in Kaplan--Meier analyses through the log-rank test. The Cox regression model was used to evaluate the hazard ratio (HR) and multivariate analysis.

Results
=======

A total of 253 patients with primary localized hepatocellular carcinoma in our study consisted of 165 males and 88 females, with an average age of 60±1.8 years. According to the TNM staging, there were 122 patients with stage I or II tumors, 131 patients with stage III or IV tumors. In view of pathology, 128 patients had well/moderately differentiated adenocarcinoma, while 125 patients with poor differentiation. Moreover, there was no statistically significant association between LMR and clinicopathologic characteristics, except TNM stage. Baseline clinicopathologic characteristics are shown in [Table 1](#t1-ott-10-1181){ref-type="table"}.

Prognostic significance of LMR for hepatocellular carcinoma
-----------------------------------------------------------

In the ROC curve analysis, we confirmed that the optimal cutoff levels for the LMR was 3.0 for OS and 3.2 for RFS. The area under the curve was 0.566 for OS and 0.652 for RFS ([Figure 1](#f1-ott-10-1181){ref-type="fig"}). The median follow-up duration was 33 months (range: 6--85 months). There were significant associations between BCLC stage, TNM stage, pathological differentiation, and LMR with OS and RFS ([Table 2](#t2-ott-10-1181){ref-type="table"}).

At the end of this study, 79 (31.2%) out of the 253 patients studied had died, including 18 (25.0%) out of 72 patients with an LMR ≥3.0 and 61 (33.7%) out of 181 patients with an LMR \<3.0. Tumor recurrence occurred in 85 (48.6%) out of 175 patients with an LMR \<3.2, and 27 (34.7%) out of 78 patients with an LMR ≥3.2. Kaplan--Meier survival analysis showed that LMR ≥3.0 was related to a shorter OS. The mean OS of patients with an LMR ≥3.0 in peripheral blood was 67 months, which is statistically significantly higher than those with an LMR \<3.0 (55 months) (67 months vs 55 months, *P*=0.023), ([Table 2](#t2-ott-10-1181){ref-type="table"}; [Figure 2](#f2-ott-10-1181){ref-type="fig"}). Otherwise, this result remained statistically significant in the multivariate analysis for OS (HR, 0.147; 95% confidence interval \[CI\]: 0.085--0.253; *P*=0.021) ([Table 2](#t2-ott-10-1181){ref-type="table"}).

In Kaplan--Meier univariate analysis of RFS, patients with high LMR (≥3.2) had higher mean RFS than patients with low LMR (\<3.2) (60 months vs 48 months, *P*=0.026). In Cox multivariate analysis, high LMR was also confirmed as a significant predictor for RFS (HR, 0.317; 95% CI: 0.042--1.023; *P*=0.032) ([Table 3](#t3-ott-10-1181){ref-type="table"}).

For advanced hepatocellular carcinoma (TNM stage III), patients with high LMR (≥3.0) had significantly longer overall mean survival than those with an LMR \<3.0 (60 months vs 45 months, *P*=0.029). Furthermore, this result remained significant for RFS (56 months vs 38 months, *P*=0.029). However, there was no statistically significant association between LMR and OS and RFS of patients with stage I and stage II cancer (for OS, 75 months vs 71 months, *P*=0.579; for RFS, 63 months vs 62 months, *P*=0.816) (see [Figure 3](#f3-ott-10-1181){ref-type="fig"}).

In subgroup analysis of age, we found that the high LMR provided an OS (70 months vs 56 months, *P*=0.036) and RFS (64 months vs 50 months, *P*=0.041) benefit for patients aged \<60 years. In patients ≥60 years, there was no significant difference between high LMR and low LMR, for OS (52 months vs 49 months, *P*=0.280) and RFS (45 months vs 41 months, *P*=0.279) (see [Figure 4](#f4-ott-10-1181){ref-type="fig"}).

A multivariate analysis entering variables such as gender, tumor size, histological differentiation type, Child-Pugh stage, LMR, TNM stage and BCLC stage, into the Cox regression model to determine independent prognostic predictors for operable hepatocellular carcinoma was performed. The result showed that LMR (HR, 0.147; 95% CI: 0.085--0.253; *P*\<0.05), TNM (HR, 5.432; 95% CI: 3.168--9.283; *P*\<0.05), pathological differentiation (HR, 0.626; 95% CI: 0.412--0.952; *P*\<0.05), and BCLC stage (HR, 6.532; 95% CI: 3.874--11.562; *P*\<0.05) were the independent prognostic factors for OS ([Table 2](#t2-ott-10-1181){ref-type="table"}). Otherwise, LMR (HR, 0.317; 95% CI: 0.042--1.023; *P*\<0.05), TNM (HR, 6.513; 95% CI: 3.167--8.522; *P*\<0.05), and BCLC stage (HR, 3.622; 95% CI: 1.374--6.542; *P*\<0.05) were the independent prognostic factors for RFS ([Table 3](#t3-ott-10-1181){ref-type="table"}).

Discussion
==========

Both experimental and clinical data indicate that inflammation plays an important role in progression and metastasis of malignancies, which are also associated with host immunity.[@b22-ott-10-1181] Lymphocytes were considered as the main components of the antitumor immune system, which were also the cellular basis of immunoediting and immunosurveillance, which can reflect antitumor immune response.[@b23-ott-10-1181] Patients with advanced malignancy present with significant lymphocytopenia, suggesting local and systemic immunosuppression, which has been confirmed as an independent prognostic factor for OS in malignancy.[@b24-ott-10-1181]--[@b26-ott-10-1181]

Tumor-infiltrating leukocytes also have an important role in the development and progression of tumor, such as neutrophils and monocytes.[@b27-ott-10-1181] The monocytes in peripheral blood includes the dendritic cells and macrophages.[@b28-ott-10-1181] Dendritic cells have an immune regulatory function, which can cause immunosuppression of patients with malignant tumors through activating Treg cells, while macrophages can kill tumor cells.[@b29-ott-10-1181],[@b30-ott-10-1181] Otherwise, the role of macrophages/monocytes in the development and progression of cancer is controversial, presenting as inhibiting as well as enhancing potential of monocytes in human cancer.[@b31-ott-10-1181] However, there is increasing evidence that the tumor-associated macrophages can prompt tumor progression.[@b32-ott-10-1181],[@b33-ott-10-1181] Furthermore, several published studies showed that increased preoperative peripheral blood monocyte count was related to poor survival in patients with cancer.[@b34-ott-10-1181],[@b35-ott-10-1181]

LMR, a biomarker related to both inflammation and immunity, can reflect the unbalanced status of inflammation and immunity, and has also been confirmed as a significant prognostic factor for several malignancies.[@b36-ott-10-1181]--[@b38-ott-10-1181] In the present study, we respectively analyzed 253 patients who underwent a curative operation for primary HBV-positive hepatocellular carcinoma, and found LMR was not only an independent prognostic factor of primary hepatocellular carcinoma, but also significantly related to TNM stage. However, the association was limited to patients with advanced hepatocellular carcinoma in subgroup analyses. It has been confirmed that advanced cancer patients who were characterized by severe inflammatory status can present as having a lower LMR.[@b39-ott-10-1181] Otherwise, LMR was highly correlated with TNM stage, thus the prognosis.

Otherwise, we found that high LMR did not represent better prognosis for patients aged less than 60 years, but for patients aged ≥60 years. It has been confirmed that the immune system deteriorates in the elderly, a phenomenon known as immunosenescence. In the setting of aging, the quality and quantity of lymphocytes decline.[@b40-ott-10-1181] Furthermore, the LMR of the elderly may be influenced, therefore not inflecting actual inflammatory status. Therefore, this study confirmed that preoperative LMR can be applied to enable pretreatment risk stratification for individual patients, and to predict post-curative resection survival for HBV-positive hepatocellular carcinoma patients. Otherwise, LMR, as a preoperative prognostic predictive marker, can be used to plan individual treatment through patient classification. In other words, patients with a high LMR need be more aggressively treated and more frequently followed-up.

Limitations
===========

There were several limitations in this study. The outcome of the retrospective design of the study cannot fully confirm the significance of LMR. It will take a larger scale multicenter prospective study to confirm the role of LMR. Furthermore, we estimated the cutoff LMR values for OS and RFS through ROC curves, which may not be applied to other studies. We are doing a meta-analysis including various LMR validation studies to confirm the optimal cutoff value for LMR.

Conclusion
==========

In conclusion, LMR, characterized as easy to perform, with general availability and affordability, could be considered as an independent prognostic predictive biomarker for operable hepatocellular carcinoma.
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![Left panel shows receiver-operator characteristic (ROC) curve for overall survival (OS), the area under the curve was 0.566 for lymphocyte-to-monocyte ratio (LMR). Right panel showed ROC curve for recurrence-free survival (RFS), the area under the curve was 0.652 for LMR.](ott-10-1181Fig1){#f1-ott-10-1181}

![Kaplan--Meier estimates of survival. Left panel showed the association between lymphocyte-to-monocyte ratio (LMR) and overall survival (OS) (mean survival in LMR ≥3.0, 67 months; in LMR \<3.0, 55 months, *P*=0.023). Right panel showed the association between LMR and recurrence-free survival (RFS) (mean survival in LMR ≥3.2, 60 months; in LMR \<3.4, 48 months, *P*=0.026).\
**Abbreviation:** Cum, cumulative.](ott-10-1181Fig2){#f2-ott-10-1181}

![TNM stage-wise survivability. Panel (**A** and **B**) showed that there was no statistically significant correlation between lymphocyte-to-monocyte ratio (LMR) and overall survival (OS) and recurrence-free survival (RFS) of patients with early stage cancer, while panel (**C** and **D**) showed there was a significant association between LMR and OS and RFS of advanced cancer patients.\
**Abbreviation:** Cum, cumulative.](ott-10-1181Fig3){#f3-ott-10-1181}

![Age-wise survivability. Panel (**A** and **C**) showed high lymphocyte-to-monocyte ratio (LMR) provided overall survival (OS) (70 months vs 56 months, *P*=0.036) and recurrence-free survival (RFS) (64 months vs 50 months, *P*=0.041) benefit for patients aged \<60 years. In panel (**B** and **D**), for patients aged ≥60 years, there was no significant difference between high LMR and low LMR, for OS (52 months vs 49 months, *P*=0.280) and RFS (45 months vs 41 months, *P*=0.279).\
**Abbreviation:** Cum, cumulative.](ott-10-1181Fig4){#f4-ott-10-1181}

###### 

Correlation between the percentage of LMR and clinicopathologic characteristics

  Characteristics                LMR   *P*-value   
  ------------------------------ ----- ----------- -------
  Age (years)                                      0.965
   ≥60                           81    32          
   \<60                          100   40          
  Sex                                              0.237
   Male                          114   51          
   Female                        67    21          
  Liver cirrhosis                                  0.695
   Yes                           152   59          
   No                            29    13          
  Child-Pugh stage                                 0.110
   A                             128   58          
   B                             53    14          
  AFP (ng/mL)                                      0.147
   ≤20                           73    22          
   \>20                          108   50          
  BCLC stage                                       0.377
   A                             131   56          
   B                             50    16          
  Tumor size (cm)                                  0.330
   ≥5.0                          80    27          
   \<5.0                         101   45          
  Tumor site                                       0.826
   Left                          56    25          
   Right                         102   39          
   Left and right                23    8           
  TNM stage                                        0.003
   I+II                          83    48          
   III                           98    24          
  Pathological differentiation                     0.905
   Well/moderate                 92    36          
   Poor                          89    36          
  Operation type                                   0.613
   Laparoscopic                  52    23          
   Open                          129   49          

**Abbreviations:** LMR, lymphocyte-to-monocyte ratio; BCLC, Barcelona Clinic Liver Cancer.

###### 

Univariate and multivariate analyses of the association of the prognostic factors with OS

  Characteristics                Univariate   Multivariate                                   
  ------------------------------ ------------ -------------- ------- ------- --------------- -------
  Age (years)                                                0.092                           
   ≥60                           113          57                                             
   \<60                          140          56                                             
  Sex                                                        0.534                           
   Male                          165          54                                             
   Female                        88           63                                             
  Liver cirrhosis                                            0.518                           
   Yes                           211          58                                             
   No                            42           58                                             
  Child-Pugh stage                                           0.204                           
   A                             186          53                                             
   B                             67           57                                             
  AFP (ng/mL)                                                0.765                           
   ≤20                           95           64                                             
   \>20                          158          66                                             
  BCLC stage                                                 0.031   6.532   3.874--11.562   0.022
   A                             187          65                                             
   B                             66           53                                             
  Tumor size (cm)                                            0.001                           
   ≥5.0                          107          63                                             
   \<5.0                         146          42                                             
  Tumor site                                                 0.632                           
   Left                          81           63                                             
   Right                         141          61                                             
   Left and right                31           58                                             
  Tumor stage                                                0.000   5.432   3.168--9.283    0.000
   I+II                          131          78                                             
   III                           122          48                                             
  Pathological differentiation                               0.045   0.626   0.412--0.952    0.028
   Well/moderate                 128          68                                             
   Poor                          125          43                                             
  Operation type                                             0.105                           
   Laparoscopic                  75           58                                             
   Open                          178          57                                             
  LMR                                                        0.023   0.147   0.085--0.253    0.021
   ≥3.0                          72           67                                             
   \<3.0                         181          55                                             

**Abbreviations:** OS, overall survival; MS, mean survival; CI, confidence interval; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; BCLC, Barcelona Clinic Liver Cancer.

###### 

Univariate and multivariate analyses of the association of the prognostic factors with RFS

  Characteristics                Univariate   Multivariate                                  
  ------------------------------ ------------ -------------- ------- ------- -------------- -------
  Age (years)                                                0.132                          
   ≥60                           113          52                                            
   \<60                          140          51                                            
  Sex                                                        0.331                          
   Male                          165          50                                            
   Female                        88           58                                            
  Liver cirrhosis                                            0.612                          
   Yes                           161          52                                            
   No                            92           54                                            
  Child-Pugh stage                                           0.213                          
   A                             186          53                                            
   B                             67           51                                            
  AFP (ng/mL)                                                0.565                          
   ≤20                           95           58                                            
   \>20                          158          52                                            
  BCLC stage                                                 0.025   3.622   1.374--6.542   0.026
   A                             187          60                                            
   B                             66           52                                            
  Tumor size (cm)                                            0.512                          
   ≥5.0                          107          59                                            
   \<5.0                         146          52                                            
  Tumor site                                                 0.821                          
   Left                          81           59                                            
   Right                         141          57                                            
   Left and right                31           54                                            
  Tumor stage                                                0.000   6.513   3.167--8.522   0.000
   I+II                          131          64                                            
   III                           122          45                                            
  Pathological differentiation                               0.042                          
   Well/moderate                 128          60                                            
   Poor                          125          40                                            
  Operation type                                             0.261                          
   Laparoscopic                  75           52                                            
   Open                          178          53                                            
  LMR                                                        0.026   0.317   0.042--1.023   0.032
   ≥3.2                          72           60                                            
   \<3.2                         181          48                                            

**Abbreviations:** RFS, recurrence-free survival; MS, mean survival; CI, confidence interval; HR, hazard ratio; LMR, lymphocyte-to-monocyte ratio; BCLC, Barcelona Clinic Liver Cancer.
